Danaher Corporation Revenue Breakdown – EUROTLX:4DHR
Danaher Corporation (EUROTLX:4DHR) reported total annual revenue of 20.92 billion EUR. The Diagnostics segment was the top performer, generating 8.46 billion EUR, while the United States was the leading regional contributor with 8.50 billion EUR in the last year.
ESCO Technologies Inc. (ESE) Stock forecasts
Argus has raised its target price for ESCO Technologies Inc. (ESE) to $365.00, citing the company's engineered products and systems used in utility, industrial, aerospace, and commercial applications. The current stock price for ESE is $327.78. Investors can access a full report for more detailed financial insights and upgrade for premium screener tools.
Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises
Edwards Lifesciences Corporation (EW) reported strong second-quarter 2026 results, with adjusted earnings of 78 cents per share and revenues of $1.74 billion, both exceeding analyst estimates. The growth was primarily driven by robust demand for Transcatheter Aortic Valve Replacement (TAVR) and increasing adoption of its mitral and tricuspid therapies. Following the positive report, the company's stock experienced a nearly 3% jump in after-hours trading, and Edwards raised its full-year sales outlook while reaffirming its earnings guidance.
Cepheid Appoints Piotr Zima Chief Information Officer
Cepheid, a Danaher Corporation subsidiary focused on molecular diagnostics, has appointed Piotr Zima as its new Chief Information Officer (CIO). Zima previously served as Vice President, Chief Information Officer at Integrated DNA Technologies and held data and analytics roles within Danaher. He expressed his excitement to continue contributing to Cepheid's mission of "Innovation at the speed of life."
BSX|Boston Scientific Corp|Price:43.590|Chg%:+0.620
Boston Scientific Corp (BSX) is trading at $43.780, up 0.46%, with a market cap of $65.07B. The company exhibits strong fundamentals including high revenue and profit growth, and is considered fairly valued in the Healthcare Equipment & Supplies industry. While institutional ownership is very high, analysts have largely rated it as a "Buy" with a target price of $75.01, despite a medium-term outlook for a downward trend.
Beacon Financial Corporation (BBT) Stock Forecasts
Argus lowered its target price for Beacon Financial Corporation (BBT) to $33.00 as of July 8, 2026, while the current stock price is $30.14. Beacon Financial Corp operates as a multi-bank holding company, providing commercial, business, and retail banking services. The full report and more detailed insights are available to premium subscribers.
BABA Stock Price | Analyst Target 198.42 & Strong Buy Consensus
Alibaba-ADR (BABA) currently trades at $111.48, down 2.26% today, with analysts setting a Strong Buy consensus and a target price of $198.42. The company, headquartered in Hangzhou, China, operates globally through various segments including Core Commerce, Cloud Computing, and Digital Media and Entertainment. Alibaba Group Holding Ltd (BABA) is described as a "Strong Buy" based on analyst consensus, with a target price of $198.42, despite its recent share price decline.
Danaher Corp. stock underperforms Thursday when compared to competitors despite daily gains
Danaher Corp. (DHR) shares rose 7.46% on Thursday, closing at $192.50, marking its second consecutive day of gains. However, this performance underperformed the broader market, as the S&P 500 Index (SPX) fell 1.21% and the Dow Jones Industrial Average (DJIA) dropped 0.97%.
Danaher Corp Stock (DHR) Moved Up by 6.78% on Jul 23: What Signal Does It Send?
Danaher Corp (DHR) stock rose 6.78% due to strong quarterly results, exceeding analyst expectations, and indicating a recovery in bioprocessing demand. Management raised full-year earnings and revenue guidance, reflecting confidence in sustainable growth across its biotechnology and life sciences segments. Broader market dynamics and institutional investor rotation into high-quality companies also contributed to the positive momentum.
Thermo Fisher stock rebounds after Q2 beat (TMO:NYSE)
Thermo Fisher Scientific (TMO) saw its stock rebound by approximately 5% in premarket trading after reporting better-than-expected Q2 2026 results. This comes after a recent decline influenced by a peer's lower outlook. The life sciences company is based in Waltham, Massachusetts.
NewEdge Wealth LLC Buys 1,675 Shares of The Goldman Sachs Group, Inc. $GS
NewEdge Wealth LLC increased its stake in The Goldman Sachs Group by 6.9% in the first quarter, purchasing an additional 1,675 shares and bringing its total holdings to 26,025 shares valued at $22,017,000. Other institutional investors also adjusted their positions in the company. Goldman Sachs recently reported strong Q2 2026 earnings, beating analyst estimates with $20.98 EPS on revenues of $20.34 billion, and announced an increased quarterly dividend of $5.00 per share.
Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF), Danaher (DHR) and TransMedics Group (TMDX)
Three analysts recently issued bullish sentiments on healthcare companies CSL (CMXHF), Danaher (DHR), and TransMedics Group (TMDX). Morgan Stanley maintained a Buy rating on CSL with a A$163.00 price target, TD Cowen reiterated a Buy rating on Danaher with a $236.00 price target, and William Blair maintained a Buy rating on TransMedics Group. All three companies received positive analyst consensus ratings, with significant upside potential noted for Danaher and TransMedics Group.
DHR Maintains Buy Rating -- Price Target Lowered to $236 by TD C
TD Cowen has maintained a Buy rating on Danaher (DHR) but lowered its price target from $240 to $236, citing adjustments based on current market dynamics. Despite the revised target, Danaher is considered undervalued by GuruFocus, trading 25.6% below its GF Value™, and holds a strong GF Score™ of 76/100, indicating solid financial performance. However, recent insider selling activity suggests a cautious sentiment among company insiders.
Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business
Repligen Corp announced its acquisition of BioLife Solutions in a $1.5 billion cash-and-stock deal, aiming to enhance its presence in the rapidly expanding cell therapy market. This acquisition grants Repligen access to BioLife's cell preservation technology, processing tools, and high-margin consumables business. The deal, unanimously approved by both boards, is anticipated to close in Q4 2026 and is expected to boost Repligen's earnings while generating at least $20 million in first-year savings.
Danaher Q2 2026 Deep Dive: EPS Beats by 4.9%, Revenue Up 6%
Danaher (DHR) reported Q2 2026 adjusted EPS of $1.94, beating estimates by 6.0%, and revenue of $6.3 billion, up 5.5% year-over-year. Despite the beat, the stock fell 14.9% due to sequential deceleration in earnings and modest 3.0% core revenue growth, alongside persistent bioprocessing headwinds. The company's strong free cash flow generation and margin expansion provide financial flexibility, but the ambitious full-year guidance suggests a need for significant second-half acceleration.
Guggenheim cuts Danaher stock price target to $200 on bioprocessing concerns
Guggenheim has lowered its price target for Danaher (NYSE: DHR) to $200 from $235, maintaining a "Buy" rating, due to ongoing concerns about the bioprocessing market despite the company surpassing Q2 2026 earnings estimates. The firm expects uncertainty in the bioprocessing segment to persist in the coming months, with 10 analysts revising earnings downward. InvestingPro's Fair Value analysis suggests the stock is currently undervalued.
Guggenheim cuts Danaher stock price target to $200 on bioprocessing concerns
Guggenheim lowered its price target for Danaher Corp. (NYSE:DHR) to $200 from $235 due to ongoing concerns about the bioprocessing market, although it maintained a Buy rating. Despite a recent beat on second-quarter earnings, investor reaction was subdued, and Stifel also reduced its price target on bioprocessing underperformance. InvestingPro data suggests the stock is currently undervalued despite the short-term headwinds, which include downward earnings revisions from multiple analysts.
Danaher Earnings: Market Underwhelmed by 2026 Guidance, Including Bioprocessing Delays
Danaher reported strong second-quarter results with 3% core revenue growth and 8% adjusted EPS growth, surpassing analyst consensus. Despite an increased EPS outlook, the market was reportedly underwhelmed due to reduced core revenue growth assumptions and anticipated bioprocessing customer delays expected to impact late 2026. This outlook suggests that while current performance is robust, future growth may face headwinds.
Danaher Stock Fell 11% After Earnings. Here’s What Could Drive It in 2026
Danaher stock fell 11% after news that substantial bioprocessing shipments were postponed until 2027, causing the company to lower its 2026 growth forecast despite beating second-quarter earnings. Analysts have mixed reactions on its price target, reflecting uncertainty about the timing of bioprocessing demand recovery. A valuation model suggests a potential upside of 37% by 2028, but this hinges on the conversion of bioprocessing orders into revenue and successful integration of Masimo.
Danaher Q2 2026 Deep Dive: EPS Beats by 4.9%, Revenue Up 6%
Danaher Corporation reported adjusted earnings of $1.94 per share in Q2 2026, exceeding estimates by 6.0%, with revenue up 5.5% year-over-year to $6.3 billion. Despite improved profitability and strong free cash flow, the stock fell 14.9% due to concerns over sequential deceleration in earnings, modest core revenue growth, and persistent bioprocessing headwinds. The market reaction indicates investor focus on future trajectory rather than past performance, with full-year guidance implying an ambitious second-half acceleration.
Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business
Repligen Corp announced its acquisition of BioLife Solutions in a cash-and-stock deal valued at approximately $1.5 billion. This acquisition aims to enhance Repligen's presence in the growing cell therapy market by integrating BioLife's cell preservation technology and cell-processing tools. The deal, expected to close in Q4 2026, also anticipates increasing Repligen's earnings and generating at least $20 million in savings during its first year.
Picard Medical announces reverse stock split
Picard Medical, Inc. announced that its Board of Directors has approved a 1-for-50 reverse stock split of the company's common stock. This decision follows stockholders' approval on July 17, 2026, to authorize a reverse stock split at a ratio ranging from 1-for-15 to 1-for-50.
Earnings call transcript: Danaher beats Q2 2026 estimates but shares sink
Danaher (DHR) reported stronger-than-expected Q2 2026 earnings and revenue, but its stock dropped significantly in premarket trading. The decline was attributed to investor concerns over adjusted guidance and shifts in bioprocessing revenue timing, despite underlying strong order trends and an aggressive share repurchase program. The company raised its full-year EPS guidance, but highlighted that over $100 million in bioprocessing revenue shifted into 2027 due to customer timing.
TOP Financial (NASDAQ:TOP) Gains Technical Focus After Warrant Exercise Update
TOP Financial Group (NASDAQ:TOP) has garnered technical attention following a warrant exercise update. The company announced the full exercise of outstanding warrants through a cashless process, impacting its share structure and broader financial services trends. This development has placed TOP Financial Group in focus among investors.
Repligen to buy cell therapy maker BioLife in $1.5 billion deal
Repligen Corp announced it will acquire BioLife Solutions for approximately $1.5 billion in a cash-and-stock deal. This acquisition will expand Repligen's presence in the growing cell therapy market by gaining access to BioLife's cell-preservation technology and processing tools. The deal is expected to increase Repligen's earnings and generate at least $20 million in first-year cost savings.
Danaher’s Q2 Earnings Call Shows Life Sciences at Its Best Quarter in Years
Danaher (DHR) delivered a strong Q2 2026 earnings report, exceeding revenue and adjusted EPS estimates, with its Life Sciences segment achieving its best quarter in years, showing 5.5% core growth. Despite a $100 million bioprocessing consumables pushout into 2027 due to customer delays, reported orders remained strong, growing mid-teens. The company raised its full-year adjusted EPS guidance and TIKR models the stock for a 53% return by December 2030.
Don’t Quit on Danaher Stock After Horrific Earnings Reaction
Danaher Corporation (DHR) experienced a significant drop in its stock price following its recent earnings report. Despite this "downbeat reaction," the article suggests that long-term investors should not abandon the stock. The author believes there are reasons for the stock to rebound, encouraging a focus on the company's long-term prospects rather than immediate market fluctuations.
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI
This article provides a roundup of rating and price target revisions by Wall Street securities analysts for various U.S.-listed companies, including Danaher, GM, and MSCI. The report details whether target prices were raised or cut and if ratings changed for a comprehensive list of companies as of Wednesday.
DevvStream Corp (DEVSF) Stock Price, News & Analyst Forecast
The article provides a current overview of DevvStream Corp (DEVSF) stock, stating its price, recent performance, and key financial metrics. It highlights that the stock price is rising this week despite a daily decrease and offers instructions on how to purchase DEVSF shares through the eToro platform. The article also includes general financial advice guides and frequently asked questions about the company.
Why Repligen (RGEN) Stock Is Trading Lower Today
Repligen (RGEN) stock is trading lower after the biopharma manufacturing company provided weak full-year guidance ahead of its Q2 earnings report. This decline was exacerbated by concerns regarding project delays highlighted by industry peer Danaher, which also saw its shares fall due to similar issues affecting bioprocessing revenue. The combination of Repligen's conservative outlook and broader sector challenges contributed to the stock's decrease.
SmartFinancial Releases Q2 2026 Financial Results
SmartFinancial, Inc. (SMBK) announced its Q2 2026 financial results, reporting operating earnings of $0.96 per share and total revenue of $78.0M. The company's EPS beat analyst forecasts by 4.3%, and revenue showed a 12.3% year-over-year increase. SmartFinancial recorded a net income of $16.3M and managed $6.12B in total assets.
Danaher shares tumble despite earnings beat
Danaher Corporation reported better-than-expected second-quarter earnings and revenue, and raised its full-year 2026 adjusted EPS guidance. However, the company's shares fell 9% premarket due to disappointing third-quarter core revenue growth guidance. Despite the market reaction, the CEO highlighted strong performance in Life Sciences and mid-teens bioprocessing orders growth.
Coca-Cola’s $1 Billion Milk Brand Just Got Hacked. Here’s What It Means For Store Shelves
Coca-Cola's Fairlife dairy subsidiary, a brand with sales surpassing $1 billion in 2022, has been hit by a ransomware attack, suspending its U.S. production. This cyberattack could lead to significant disruptions in grocery store availability across the nation, similar to past incidents affecting Arizona Beverages and UNFI, due to Fairlife's prominent position in the protein-fortified dairy market with few direct competitors. While Coca-Cola has confirmed product quality and safety are unaffected, the lack of a restoration timeline and information on stolen data or ransom demands raises concerns about potential prolonged shortages.
Danaher Corporation 2026 Q2 - Results - Earnings Call Presentation (NYSE:DHR) 2026-07-21
Danaher Corporation has published its 2026 Q2 earnings call presentation. This article by SA Transcripts provides access to the slide deck presented by Danaher in conjunction with their earnings call. SA Transcripts is responsible for publishing thousands of quarterly earnings calls and is continually expanding its coverage.
Danaher (DHR) Q2 2026 earnings summary
Danaher (DHR) reported strong Q2 2026 results, with revenue growing 5.5% to $6.3 billion and adjusted diluted EPS up 8% to $1.94. The company raised its full-year adjusted EPS guidance to $8.45–$8.60, driven by the early completion of the Masimo acquisition and robust order trends. While Life Sciences and Diagnostics segments performed well, Biotechnology growth moderated, and the company provided a Q3 core revenue growth outlook of 2-3%.
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market
Danaher Corp (NYSE: DHR) shares dropped by 10.1% in pre-market trading despite reporting better-than-expected Q2 adjusted EPS and sales. Other companies also saw significant declines in pre-market trading, including Calix Inc and Equifax Inc, following their Q2 results or financial announcements. The broad market, however, saw Nasdaq 100 futures trading higher.
Danaher Corporation (DHR) Q2 2026 earnings beat estimates; revenue up 5.5%
Danaher Corporation (DHR) reported stronger-than-expected adjusted earnings for Q2 2026, reaching $1.94 per share, surpassing estimates of $1.84 per share. The company's revenue increased by 5.5% year-over-year to $6.27 billion, also beating top-line estimates. Core revenue grew by 3.0%, with Life Sciences businesses achieving their strongest quarter in several years.
Danaher Corporation (DHR) Q2 2026 earnings beat estimates; revenue up 5.5%
Danaher Corporation (DHR) reported stronger-than-expected adjusted earnings of $1.94 per share for Q2 fiscal 2026, surpassing analyst estimates of $1.84. The company's revenues increased by 5.5% year-over-year to $6.27 billion, also exceeding expectations. CEO Rainer Blair highlighted improved core growth, strong performance in Life Sciences, and mid-teens bioprocessing order growth despite some customer project timing impacts.
KeyCorp (KEY) Tops Q2 EPS by 2c
KeyCorp (NYSE: KEY) announced its Q2 earnings, reporting an EPS of $0.44, which is $0.02 higher than the analyst estimate of $0.42. The company's revenue for the quarter was $1.96 billion, slightly below the consensus estimate of $1.97 billion.
Danaher Q2 earnings jump 60% YoY, raises full-year profit forecast on strong growth and Masimo deal.
Danaher Corporation announced a 60% year-over-year increase in Q2 2026 net earnings, reaching $870 million, primarily due to robust core growth and the swift acquisition of Masimo. Revenues climbed 5.5% to $6.3 billion, with adjusted earnings per share rising 8% to $1.94. The company has consequently raised its full-year adjusted EPS guidance to $8.45-$8.60, anticipating mid-single-digit core revenue growth.
Danaher shares tumble despite earnings beat
Danaher Corporation reported better-than-expected Q2 earnings and revenue, and raised its full-year EPS guidance. Despite this, the company's shares fell 9% premarket due to disappointing Q3 core revenue growth guidance. The life sciences segment showed strong performance, while bioprocessing revenue was impacted by customer project timing.
Earnings Flash (DHR) Danaher Corporation Reports Q2 Revenue $6.27B, vs. FactSet Est of $6.11B
Danaher Corporation (DHR) reported its Q2 revenue at $6.27 billion, surpassing FactSet's estimate of $6.11 billion. This earnings flash was published by MT Newswires, indicating Danaher's stronger-than-expected financial performance for the second quarter. The company also raised its 2026 guidance and posted adjusted EPS of $1.94, exceeding the FactSet estimate of $1.84.
Danaher: Q2 Earnings Snapshot
This article provides a brief earnings snapshot for Danaher's Q2 performance. Due to the limited content, specific financial details are not available.
Danaher reports Q2 2026: Revenue $6.27B, Net earnings $870M, Adj. diluted EPS $1.94
Danaher reported robust Q2 2026 financial results with revenue of $6.27 billion and net earnings of $870 million. The company's adjusted diluted EPS grew 8.0% year-over-year to $1.94, and it generated significant operating and free cash flow. Danaher also raised its full-year 2026 adjusted EPS guidance, underscoring strong business performance and strategic acquisitions.
Danaher 2Q 2026: Revenue $6.27B, EPS $1.23— 10-Q Summary
Danaher reported strong second-quarter 2026 results with revenue of $6.27 billion and diluted EPS of $1.23, reflecting a significant year-over-year increase in net income to $870 million. The company's growth was driven by core sales, particularly in Life Sciences and Biotechnology, and the acquisition of Masimo, which expanded its Diagnostics acute-care product set. High-growth markets contributed significantly, offsetting flatter performance in developed regions.
Crude Oil Surges 2%; 3M Shares Gain After Q2 Results
U.S. stocks saw broad gains with the Dow Jones index climbing over 350 points, led by a 2% jump in information technology shares. 3M Company (NYSE: MMM) shares surged over 9% after reporting better-than-expected second-quarter results and raising its full-year guidance. Crude oil also rose by 2.1%, while major European and Asian markets showed mixed performance.
Danaher: Q2 Earnings Snapshot
Danaher Corp. (DHR) reported a second-quarter profit of $870 million, or $1.23 per share, with adjusted earnings of $1.94 per share, surpassing Wall Street's expectations of $1.84 per share. The company's revenue reached $6.27 billion, exceeding the anticipated $6.09 billion. Danaher projects full-year earnings to be between $8.45 and $8.60 per share.
Danaher leads volatile earnings moves with $7.58 billion at stake
Danaher Corp. is set to lead significant earnings-related market volatility with a potential $7.58 billion market value swing, as options price a 5.30% move ahead of its Q2 2026 earnings report. Interactive Brokers Group shows the highest implied volatility on the watchlist at 6.20%, while Annaly Capital Management is the most stable with a 2.36% implied move. This report highlights key financial expectations and market cap exposure for several companies reporting earnings on July 21, 2026.
Danaher Could Swing $7.33 Billion in Value After Earnings
This article examines the implied stock movements for several companies reporting earnings on July 21, 2026, based on options market data. Danaher Corp. is highlighted for a potential 5.30% swing, equivalent to $7.58 billion in market value, due to its mega-cap status and investor reliance on fresh confidence from the quarter's results and outlook. Other companies discussed include Annaly Capital Management, Charles Schwab, EQT Corp, 3M Company, D.R. Horton Inc., and Interactive Brokers Group, with implied moves ranging from 2.36% to 6.20%.
Danaher Corp. stock underperforms Monday when compared to competitors
Shares of Danaher Corp. (DHR) fell 1.33% to $201.11 on Monday, marking its second consecutive day of losses. The underperformance occurred during a generally grim trading session where the S&P 500 Index dropped 0.19% and the Dow Jones Industrial Average declined 0.59%.
